RepliCel Retains O&M Partners to Coordinate North American Focused Investor Marketing Campaign

RepliCel Retains O&M Partners to Coordinate North American Focused Investor 
Marketing Campaign 
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/20/14 --  
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today
announced that it has retained O&M Partners, LLC to assist in
targeting non-deal institutional and independent money managers
throughout the United States including financial centres often
overlooked by biotech companies. This marketing effort will include a
combination of group Town Hall conference calls and follow-up
roadshows. With the commencement of three human clinical trials
before year-end, management is dedicated to meeting as many non-deal
investors as possible. This campaign is an integral part of the
company's overall marketing effort focused on the United States. 
O&M Partners, LLC is internationally recognised by institutional and
independent money managers for its ability to discover high-potential
companies, identify sector trends, and qualify market sentiment.
Since 1995, O&M's New York-based marketing professionals have been
bringing Wall Street together with the senior management of publicly
traded companies on the TSX, AMEX and NASDAQ. O&M specializes in
non-deal institutional marketing of micro-and small-caps. 
About RepliCel Life Sciences  
RepliCel is a regenerative medicine company focused on developing
autologous cell therapies that address diseases caused by a deficit
of healthy cells required for normal healing and function such as
chronic tendinosis, damaged skin and pattern baldness. The company's
RCT-01 and RCS-01 cell therapies are designed to treat chronic
tendinosis and damaged or aging skin respectively, using fibroblasts
isolated from the sheath of the hair follicle. Another of the
company's pipeline products, RCH-01 for the treatment of pattern
baldness, is manufactured from cells derived from the hair follicle
dermal cup. Shiseido Company, Limited has an exclusive geographic
license for RCH-01 in certain Asian countries including Japan, China
and South Korea. All product candidates are based on RepliCel's
innovative technology which utilizes cells isolated from a patient's
own healthy hair follicles to address specific cellular deficits. For
additional information please visit  
On Behalf of the Board  
RepliCel Life Sciences Inc. 
David Hall, President and Chief Executive Officer   
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 
RepliCel Life Sciences
Tammey George, Director of Communications
Westwicke Partners, LLC
Robert H. Uhl, Managing Director
Christina Cameron
Press spacebar to pause and continue. Press esc to stop.